Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M707571200 on January 10, 2008

J. Biol. Chem., Vol. 283, Issue 11, 6826-6831, March 14, 2008
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/11/6826    most recent
M707571200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, X.-Q.
Right arrow Articles by Peoples, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, X.-Q.
Right arrow Articles by Peoples, R. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The 5-HT3B Subunit Confers Spontaneous Channel Opening and Altered Ligand Properties of the 5-HT3 Receptor*Formula

Xiang-Qun Hu1 and Robert W. Peoples

From the Department of Biomedical Sciences, College of Health Sciences, Marquette University, Milwaukee, Wisconsin 53201-1881

Received for publication, September 10, 2007 , and in revised form, December 19, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Current receptor theory suggests that there is an equilibrium between the inactive (R) and active (R*) conformations of ligand-gated ion channels and G protein-coupled receptors. The actions of ligands in both receptor types could be appropriately explained by this two-state model. Ligands such as agonists and antagonists affect receptor function by stabilizing one or both conformations. The 5-HT3 receptor is a member of the Cys-loop ligand-gated ion channel superfamily participating in synaptic transmission. Here we show that co-expression of the 5-HT3A and 5-HT3B receptor subunits in the human embryonic kidney (HEK) 293 cells results in a receptor that displays a low level of constitutive (or agonist-independent) activity. Furthermore, we also demonstrate that the properties of ligands can be modified by receptor composition. Whereas the 5-hydroxytryptamine (5-HT) analog 5-methoxyindole is a partial agonist at the 5-HT3A receptor, it becomes a "protean agonist" (functioning as an agonist and an inverse agonist at the same receptor) at the 5-HT3AB receptor (after the Greek god Proteus, who was able to change his shape and appearance at will). In addition, the 5-HT analog 5-hydroxyindole is a positive allosteric modulator for the liganded active (AR*) conformation of the 5-HT3A and 5-HT3AB receptors and a negative allosteric modulator for the spontaneously active (R*) conformation of the 5-HT3AB receptor, suggesting that the spontaneously active (R*) and liganded active (AR*) conformations are differentially modulated by 5-hydroxyindole. Thus, the incorporation of the 5-HT3B subunit leads to spontaneous channel opening and altered ligand properties.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
LGICs2 are transmembrane proteins that mediate synaptic transmission upon binding of neurotransmitters at the chemical synapse. All of the LGICs are formed by the assembly of homologous subunits. The 5-hydroxytryptamine type 3 (5-HT3) receptor, a member of the Cys-loop LGIC superfamily, which includes nicotinic acetylcholine, {gamma}-aminobutyric acid, type A (GABAA), and glycine receptors (1), can exist in either homomeric (5-HT3A) or heteromeric (5-HT3AB) forms. Although the 5-HT3B receptor subunit itself cannot form functional channels, when co-expressed with the 5-HT3A receptor subunit it alters biophysical properties (2–4) and reduces allosteric modulation by alcohol and anesthetics (5–7). In the absence of agonist, channel opening of the 5-HT3A receptor is theoretically possible but has not been observed experimentally. However, certain mutations in the 5-HT3A receptor, such as 5-HT3A V13'S (V291S), have produced spontaneously opening channels (8, 9). The constitutive activity of the 5-HT3A V13'S mutant can be enhanced by incorporation of the 5-HT3B subunit (9), which may indicate that the heteromeric 5-HT3AB receptor is able to open spontaneously in the absence of agonist.

LGICs exist in two general classes of states: inactive (closed) and active (open), and each of these classes may contain multiple states that differ in average lifetime, agonist site occupancy, etc. The function of LGICs is determined by the transitions among these states. However, the mechanism for receptor activation is not completely understood. Based on observations on ligand-gated ion channels, a two-state model of receptor activation was proposed by del Castillo and Katz in 1957 (10) (Fig. 1). The del Castillo-Katz mechanism represents a sequential model, which suggests that the receptor is inactive in the absence of agonist and the binding of agonist to the inactive state (R) induces a conformational change of the receptor to an activated state (R*). Monod, Wyman, and Changeux (1965) proposed that the oligomeric proteins can undergo reversible transitions between discrete conformations such as R {leftrightarrow} R* in the absence of agonist (11). This concept was supported by the finding of constitutive activity in GPCRs first reported by Costa and Herz in 1989 (12). Because the del Castillo-Katz mechanism does not predict spontaneous channel opening in the absence of agonist, a modified two-state model was established (Fig. 1) (13). According to this model, receptors exist in a conformational equilibrium between R and R* of the unliganded receptor; and compounds alter receptor function by causing a re-distribution between the two states. An agonist preferentially binds and stabilizes the R* conformation, and an inverse agonist preferentially binds and stabilizes the R conformation. A neutral antagonist binds equally to both conformations. Although this allosteric two-state model could adequately explain most receptor behavior, it remains unknown whether the spontaneously active (R*) and liganded active (AR*) conformations are the same and whether AR* conformations are the same for different agonists (14).


Figure 1
View larger version (10K):
[in this window]
[in a new window]

  		FIGURE 1.
Two-state models of receptor activation by agonists.

 

   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Complementary DNA Constructs and Transfection—5-HT3A (gift from Dr. D. Julius) and 5-HT3B (gift from Dr. E. F. Kirkness) receptor subunits were subcloned into the vector pcDNA3.1 (Invitrogen). HEK 293 cells were transiently transfected with the 5-HT3A or 5-HT3A and 5-HT3B receptor cDNA using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Green fluorescent protein (pGreen Lantern, Invitrogen) was co-expressed with the 5-HT3 receptor subunits to permit selection of transfected cells under fluorescence optics.

Patch Clamp Electrophysiology—Whole-cell patch clamp recordings were performed as described previously (15), in HEK cells transfected with 5-HT3 receptors and green fluorescent protein. The external solution contained (in mM): 140 NaCl, 5 KCl, 1.8 CaCl2, 1.2 MgCl2, 10 glucose, and 10 HEPES (pH 7.4 with NaOH and ~340 mosmol liter–1 with sucrose). Patch pipettes contained (in mM) 140 CsCl, 2 MgCl2, 10 EGTA, and 10 HEPES (pH 7.2 with CsOH and ~315 mosmol liter–1 with sucrose).

Data Analysis—Data were acquired using pCLAMP 9.0 software (Axon). Currents were filtered at 2 kHz and digitized at 5–10 kHz. Data analysis and curve-fitting were performed with Origin 7.0 (Microcal), pCLAMP 9.0 (Axon), or GraphPad InStat 3.0 (GraphPad) software. Data are presented as mean ± S.E.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Incorporation of the 5-HT3B Subunit Alters Desensitization Kinetics of the 5-HT3 Receptor—The heteromeric 5-HT3AB receptor was transiently expressed in the HEK 293 cells, and the successful incorporation of the 5-HT3B receptor subunit was confirmed by examining the desensitization kinetics. The transfected cells were exposed to a maximally efficacious concentration of 5-HT (30 µM) for 10 s. In the continued presence of the agonist the 5-HT current decayed after reaching a peak in the 5-HT3A and 5-HT3AB receptors, a process representing receptor desensitization (Fig. 2A). The desensitization was gradual and monoexponential in the 5-HT3A receptor. However, the current decay was much faster and biexponential in the 5-HT3AB receptor. The overall desensitization measured as weighted desensitization was ~6-fold faster in the 5-HT3AB receptor than in the 5-HT3A receptor (Fig. 2B).

Spontaneous Channel Opening of the 5-HT3AB Receptor Is Conferred by the 5-HT3B Subunit—The possibility of spontaneous opening of the 5-HT3AB receptor was examined by exposing the transfected cells to the 5-HT3 receptor antagonist MDL 72222 and 5-HT analogs 5-methoxyindole (5-MI) and 5-hydroxyindole (5-HI) (see supplemental Fig. 1 for chemical structures). We first tested the actions of the 5-HT3 receptor antagonist MDL 72222 (Fig. 3A). MDL 72222 was previously used to detect spontaneous channel openings of Arg-246 mutant 5-HT3A receptors (8). Consistent with previous studies (15, 16), at a holding potential of –60 mV, MDL 72222 (1 µM) did not alter the base-line current at the 5-HT3A receptor. However, an application of MDL 72222 produced a decrease in the base-line current (manifesting as an apparent outward current) at the 5-HT3AB receptor that was 1.2 ± 0.4% of the amplitude of the 30 µM 5-HT-activated response. This is consistent with a low level of constitutive activity of the 5-HT3AB receptor due to spontaneous opening of the channels. The apparent outward current persisted for more than 20 s after removal of MDL 72222, which is most probably the result of the high affinity of MDL 72222 for the receptor. We also used Zn2+ (1 mM), an open channel blocker at the 5-HT3 receptor,3 to examine constitutive activity of the 5-HT3 receptors (Fig. 3B). Co-application of Zn2+ with 5-HT rapidly brought 5-HT-activated current to base-line levels in the 5-HT3A receptor due to blocking of the open channels. Interestingly, Zn2+ produced an overshoot above the base line during application of 5-HT in the 5-HT3AB receptor, suggesting that the activity of the 5-HT3AB receptor is suppressed below its spontaneous opening state. This overshoot current provides further evidence for the existence of constitutive activity of the 5-HT3AB receptor.


Figure 2
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 2.
Altered desensitization kinetics with the incorporation of the 5-HT3B receptor subunit. A, whole-cell currents evoked by 30 µM 5-HT for 10 s in HEK 293 cells expressing the 5-HT3 receptors show the desensitization of the 5-HT3A and 5-HT3AB receptors at a holding potential of –60 mV. Currents were normalized to peak current and superimposed to compare the desensitization kinetics between the 5-HT3A (black) and 5-HT3AB (gray) receptors. B, bar graph summarizes the overall desensitization kinetics.

 
5-HT Analogs Reveal Distinct Active Conformations of the 5-HT3AB Receptor—The use of 5-HT analogs (supplemental Fig. 1) also revealed the constitutive activity of the 5-HT3AB receptor. The 5-HT analog 5-MI functioned as a partial agonist at the 5-HT3A receptor (Fig. 4A). A rebound current appeared upon termination of 5-MI application. The maximal response activated by 5 mM 5-MI was ~34.4 ± 3.3% of the response activated by 30 µM 5-HT at –60 mV. At the 5-HT3AB receptor 5-MI displayed unusual behavior. 5-MI (5 mM) evoked a transient inward current followed by an apparent outward current (Fig. 4A). The amplitude of the inward current was 3.5 ± 0.7% of that activated by 30 µM 5-HT at –60 mV, which is significantly reduced when compared with the 5-HT3A receptor (p < 0.01, Student's t test). This finding suggests that the efficacy of 5-MI is reduced in the 5-HT3AB receptor. The amplitude of the apparent outward current was 0.9 ± 0.1% of 30 µM 5-HT-activated response. This action of 5-MI was readily reversible, and there was also a rebound current upon removal of 5-MI. The characteristics of 5-MI activation at negative and positive holding potentials were similar in the 5-HT3A receptor and in the 5-HT3AB receptor (Fig. 4B), with the exception that the direction of the currents was reversed. The observation that 5-MI produced both a transient inward current and a persistent apparent outward current at negative holding potentials is consistent with both positive and negative (inverse) agonism at the 5-HT3AB receptor.


Figure 3
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 3.
Constitutive activity in the 5-HT3AB receptor is determined by the 5-HT3B receptor subunit. A, current traces show the responses elicited by 30 µM 5-HT (left) and 1 µM MDL 72222 (right) alone in HEK 293 cells expressing the 5-HT3A and 5-HT3AB receptors. Drug applications were separated by 2-min intervals to ensure complete drug washout and the return of the current to base-line. The dashed line indicates the base-line current level. B, current traces show the actions of Zn2+ (1 mM) on 30 µM 5-HT-activated responses in the 5-HT3A and 5-HT3AB receptors. Insets, actions of Zn2+ with expanded scales. The dashed line indicates the base-line current level.

 


Figure 4
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 4.
Incorporation of the 5-HT3B receptor subunit alters the properties of the 5-HT analog 5-MI. A, current traces show the responses elicited by 30 µM 5-HT (left) and 5 mM 5-MI alone (right) in HEK 293 cells expressing the 5-HT3A and 5-HT3AB receptors at a holding potential of –60 mV. The drug application protocol was similar to that described in Fig. 3A. B, current traces show the effect of holding potentials on 5-MI-evoked currents in the 5-HT3A and 5-HT3AB receptors. The dashed line indicates the base-line level.

 
We also explored the actions of 5-HI, an analog of 5-HT that is a positive allosteric modulator of the 5-HT3 receptor (17, 18). 5-HI (5 mM), when co-applied with 5-HT (30 µM) following a delay of 250 ms or 10 s, enhanced the current amplitude by 17.1 ± 1.3% and 14.5 ± 1.0%, respectively, in the 5-HT3A receptor (Fig. 5A). Similar applications of 5-HI during the course of agonist application enhanced agonist-activated steady-state current by 66.7 ± 7.8% for 5-HT and 53.7 ± 1.5% for dopamine (a partial agonist) in the 5-HT3AB receptor (Fig. 5B). A pure positive allosteric modulator facilitates agonist-mediated receptor activity without intrinsic agonism. As expected, 5-HI alone did not change the base-line current in the 5-HT3A receptor in the absence of agonist. Unlike 5-MI, 5-HI did not activate a transient inward current but only induced an apparent outward current in the 5-HT3AB receptor. This apparent outward current was rapidly reversible upon removal of 5-HI (Fig. 5C) and had an amplitude that was 1.1 ± 0.3% of that activated by 30 µM 5-HT. Therefore, 5-HI selectively produces negative (inverse) agonism but not the positive agonism seen with 5-MI in the 5-HT3AB receptor. As was the case for 5-MI, there was a rebound current upon the removal of 5-HI. The occurrence of the rebound current has also been observed for other negative allosteric modulators or inverse agonists such as bicuculline at the {alpha}1β3{gamma}2L GABAA receptor (19), 17{alpha}-methyltestosterone at the {alpha}2β3{epsilon} GABAA receptor (20), and strychnine at the D97R glycine receptor (21). The nature of the rebound current is not clear at present; it likely represents a rapid unbinding of 5-MI or 5-HI from a low affinity site.

The other 5-HT analog 3-(2-hydroxyethyl)indole acted as an agonist in both the 5-HT3A and 5-HT3AB receptor, although the relative efficacy of 3-(2-hydroxyethyl)indole was dramatically reduced by the incorporation of the 5-HT3B subunit (17.0 ± 1.3% -> 2.0 ± 0.4%; supplemental Fig. 2). This observation implies that the hydroxyl (for 5-HI) or methoxyl (for 5-MI) group at position 5 of the indole molecule is required for detecting spontaneous activity of the 5-HT3AB receptor.

Properties of the Constitutive Activity of the 5-HT3AB Receptor—The nature of the 5-HI current was further examined by studying the current-voltage (I-V) relationship and reversal potential. The I-V relationship of the 5-HI current is symmetrical to that of 5-HT current in the 5-HT3AB receptor. Whereas the 5-HT current showed inward rectification, the 5-HI current displayed apparently outward rectification (Fig. 6). The 5-HI current reversed at 3.3 ± 0.4 mV, which is comparable to the reversal potential for 5-HT at the 5-HT3AB receptor (2.9 ± 0.3 mV). Those observations suggest that the constitutive activity is mediated by the 5-HT3AB receptor and that both the spontaneously active and ligand-activated receptors have the same ionic permeability. The onset of blocking the spontaneously active channel displayed 5-HI concentration dependence, whereas the offset of blocking was largely independent of 5-HI concentrations (supplemental Fig. 3, A and B). The rate of blocking (1/{tau}Block) is linear with 5-HI concentration with a slope of 5.9 x 104 M–1s–1 (kon, 5-HI binding rate, supplemental Fig. 3C). The y-axis intercepts were similar for linear regression fitting of 1/{tau}Block and 1/{tau}Unblock, being 4.5 s–1 and 4.8 s–1, respectively (koff, 5-HI unbinding rate). Therefore, the equilibrium dissociation constant (Ki) for 5-HI blocking the spontaneous channel opening is ~7.5 mM.


Figure 5
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 5.
Effects of the 5-HT analog 5-HI on liganded and unliganded active states. A, current traces show 5-HI enhancement of 5-HT-evoked currents in HEK 293 cells expressing the 5-HT3A receptor. Insets, superimposed traces showing the potentiation of 5-HT response by 5-HI. B, current traces show 5-HI enhancement of 5-HT- and dopamine (DA)-evoked currents in the HEK 293 cells expressing 5-HT3AB receptor. C, current traces show the responses elicited by 30 µM 5-HT (left) and 5 mM 5-HI alone (right) in the 5-HT3A and 5-HT3AB receptors. The drug application protocol was similar to that described in Fig. 3A. The dashed line indicates the base-line current level.

 


Figure 6
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 6.
5-HI current is mediated by the 5-HT3AB receptor. A, current traces evoked by 3 µM 5-HT and 5 mM 5-HI at different holding potentials in HEK 293 cells transfected with the 5-HT3AB receptor. B, current-voltage (I-V) relationship for 5-HT- and 5-HI-evoked currents. Data are normalized to the current amplitude obtained at –80 mV. Similar results were obtained from 4 to 5 cells.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Most GPCRs and LGICs exhibit a low to negligible level of constitutive activity. However, the level of constitutive activity can be enhanced by mutations and overexpression (14, 22, 23). In addition, certain receptor subunit combinations in LGICs exhibit constitutive activity (24). In the 5-HT3A receptor the energy barrier for channel opening is sufficiently high to prevent spontaneous openings in the absence of agonist. The shifts of base-line current by MDL 72222 in the absence of agonist and Zn2+ in the presence of agonist support the existence of constitutive activity in the 5-HT3AB receptor. The 5-HT3B subunit does not form functional homomeric receptors, but the observations in this study indicate that it has a lower energy barrier to channel opening relative to the 5-HT3A subunit. It is not currently clear how structural constraints keep the unliganded 5-HT3A receptor in the inactive conformation and how the incorporation of the 5-HT3B receptor subunit disrupts these structural constraints. The amino acid sequence of the 5-HT3B receptor subunit has only ~45% homology with the 5-HT3A receptor subunit (2, 3). A recent study using atomic force microscopy has revealed that the 5-HT3AB receptor is formed by two 5-HT3A subunits and three 5-HT3B receptor subunits (25). The conformational change associated with ion channel opening in 5-HT3 receptors is proposed to involve a rotation of the M2 helices (26). Although the precise number of subunits that must undergo the conformational change to open the channel is unclear at present, results from nicotinic acetylcholine receptors would suggest that two activated subunits may be sufficient to open the channel (27). Constitutive activity is determined by the equilibrium between the two interconvertible conformations R and R*. If the 5-HT3B subunit is indeed able to spontaneously undergo this conformational change, the stoichiometry of the 5-HT3AB receptor (B-B-A-B-A) would thus make it likely that some channels could spontaneously open in the absence of agonist due to altering the equilibrium constant between R and R*.

Since the description of the constitutive activity in a GPCR by Costa and Herz in 1989 (12), a variety of compounds originally described as antagonists have been shown to exhibit effects opposite to those of agonists (i.e. suppressing constitutive activity) and have thus been reclassified as inverse agonists. The observation that MDL 72222, a traditional 5-HT3 receptor antagonist, inhibits constitutive activity suggests that this compound could function as an inverse agonist at the 5-HT3AB receptor. In addition, based on theoretical grounds, Kenakin (23, 28) proposed that positive agonism could revert to negative (inverse) agonism and referred to this as "protean agonism" after the Greek god Proteus who could change his shape and appearance at will. This phenomenon has also been termed as functional selectivity, agonist-directed trafficking of receptor stimulus, and biased agonism (29). A protean agonist is a positive agonist in a quiescent system and an inverse agonist in a constitutive system. GPCRs are usually linked to multiple signal transduction pathways, so that a protean agonist could selectively enhance one or more pathways but depress the others. The existence of compounds that exhibit protean agonism was later confirmed in GPCRs (30). In contrast to GPCRs, LGICs are coupled to a single ion-permeation pathway, and protean agonism has not been observed. Our observations in the present study confirm the existence of protean agonism in LGICs.

The 5-HT3A receptor represents a quiescent receptor system because it does not exhibit constitutive activity. Therefore, in the 5-HT3A receptor 5-MI is a classical del Castillo-Katz agonist that enhances the R -> AR* transition. However, the R and R* conformations co-exist in the 5-HT3AB receptor. According to the two-state model, 5-MI could bind to both forms and enhance both the R -> AR* and R* -> AR* transitions leading to agonism. Furthermore, 5-MI, perhaps by an action at an additional site, could also promote the R* -> R transition to produce an inverse agonism. Therefore, both agonism and inverse agonism (i.e. protean agonism) could be observed for 5-MI at the 5-HT3AB receptor. Mutations in the transmembrane 2 domain (at the 12' position) of the muscle nicotinic acetylcholine receptor create spontaneously opening channels that are accompanied by a conformational change at the binding sites (31). Such a conformational change might prevent the agonist from binding to the binding pocket and impede the R* -> AR* isomerization. The actions of 5-MI in the 5-HT3AB receptor seem to be consistent with this scheme. The major event for receptor activation would then still follow the del Castillo-Katz mechanism even in the constitutively active system (supplemental Fig. 4). Here we present evidence showing that 5-MI operates as an agonist in the 5-HT3A receptor and an agonist and an inverse agonist in the 5-HT3AB receptor. It is unlikely that a ligand binds to the same site to induce different conformational changes. We propose that the agonism and inverse agonism of 5-MI are mediated by binding to two distinct sites.

According to the two-state model, an agonist has high affinity for the R* conformation and shifts the balance to the R* conformation. Hence, the R* conformation is assumed to be the same as the AR* conformation. Here we demonstrate that 5-MI displays both agonism and inverse agonism at the 5-HT3AB receptor. Furthermore, our results reveal that 5-HI is a positive modulator when the receptor is in the AR* conformation and a negative modulator (inverse agonist) when the receptor is in the R* conformation (supplemental Fig. 4). If the R* and AR* share the same conformation we would expect an enhanced base-line current by 5-HI in the absence of agonist in the 5-HT3AB receptor. It is likely that 5-HI may interact with discrete sites to exert different efficacies leading to alterations in the transition equilibrium between states. The other possible explanation to our observations is that R* and AR* may represent two distinct conformations. This notion needs to be explored in future studies.

5-HT itself is an agonist at 5-HT3 receptors. However, our observations that 5-HT analogs such as 5-MI and 5-HI can selectively modulate different active conformations in the 5-HT3 receptor suggest that subtle changes in chemical structure of an agonist can dramatically alter the functional properties. Therefore, modifications of the structure of 5-HT, 5-HI, and 5-MI may generate useful tools to study the 5-HT3 receptor mechanism and ligand-receptor interaction and could lead to the development of therapeutic agents that selectively act on specific kinetic states of the 5-HT3 receptor. In addition to constitutive activity, receptors can also be tonically activated by low concentrations of ligands such as neurotransmitters and hormones in vivo (32). Therefore, the positive and negative allosterism of 5-HI can also be a useful tool to distinguish constitutive activity from tonic activity. 5-MI and 5-HI are a partial agonist and a positive allosteric modulator, respectively, in the 5-HT3A receptor. The incorporation of the 5-HT3B receptor subunit results in the altered properties of these two ligands. Therefore, the subunit composition of the 5-HT3 receptor could regulate its biophysical and pharmacological properties. Taken together, our results suggest that the activity profile of a ligand is determined by the properties of both the ligand and receptor.

In summary, our study demonstrates that the 5-HT3B receptor subunit imparts constitutive receptor activity to the 5-HT3 receptor. The occurrence of the constitutive activity leads to alterations in the pharmacological properties of 5-HT analogs. These findings provide new insights into the receptor activation mechanism and may hold promise for the development of new therapeutic agents.


   FOOTNOTES
 
* This work was supported by institutional funds from Marquette University and by National Institutes of Health Grant AA015203 (to R. W. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1–4. Back

1 To whom correspondence should be addressed: Dept. of Biomedical Sciences, Marquette University, P. O. Box 1881, Milwaukee, WI 53201-1881. Tel.: 414-288-6679; Fax: 414-288-6564; E-mail: xiangqun.hu{at}marquette.edu.

2 The abbreviations used are: LGIC, ligand-gated ion channel; 5-HT, 5-hydroxytryptamine; 5-MI, 5-methoxyindole; 5-HI, 5-hydroxyindole; GABAA, {gamma}-aminobutyric acid, type A; GPCR, G protein-coupled receptor. Back

3 X.-Q. Hu, unpublished data. Back


   ACKNOWLEDGMENTS
 
We thank Drs. David Wagner, Michelle Mynlieff, and Hong Ren for helpful discussions.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Karlin, A. (2002) Nat. Rev. Neurosci. 3, 102–114[CrossRef][Medline] [Order article via Infotrieve]
  2. Davies, P. A., Pistis, M., Hanna, M. C., Peters, J. A., Lambert, J. J., Hales, T. G., and Kirkness, E. F. (1999) Nature 397, 359–363[CrossRef][Medline] [Order article via Infotrieve]
  3. Dubin, A. E., Huvar, R., D'Andrea, M. R., Pyati, J., Zhu, J. Y., Joy, K. C., Wilson, S. J., Galindo, J. E., Glass, C. A., Luo, L., Jackson, M. R., Lovenberg, T. W., and Erlander, M. G. (1999) J. Biol. Chem. 274, 30799–30810[Abstract/Free Full Text]
  4. Hapfelmeier, G., Tredt, C., Haseneder, R., Zieglgansberger, W., Eisensamer, B., Rupprecht, R., and Rammes, G. (2003) Biophys. J. 84, 1720–1733[Medline] [Order article via Infotrieve]
  5. Solt, K., Stevens, R. J., Davies, P. A., and Raines, D. E. (2005) J. Pharmacol. Exp. Ther. 315, 771–776[Abstract/Free Full Text]
  6. Stevens, R., Rusch, D., Solt, K., Raines, D. E., and Davies, P. A. (2005) J. Pharmacol. Exp. Ther. 314, 338–345[Abstract/Free Full Text]
  7. Hayrapetyan, V., Jenschke, M., Dillon, G. H., and Machu, T. K. (2005) Brain Res. Mol. Brain Res. 142, 146–150[Medline] [Order article via Infotrieve]
  8. Zhang, L., Hosoi, M., Fukuzawa, M., Sun, H., Rawlings, R. R., and Weight, F. F. (2002) J. Biol. Chem. 277, 46256–46264[Abstract/Free Full Text]
  9. Bhattacharya, A., Dang, H., Zhu, Q. M., Schnegelsberg, B., Rozengurt, N., Cain, G., Prantil, R., Vorp, D. A., Guy, N., Julius, D., Ford, A. P., Lester, H. A., and Cockayne, D. A. (2004) J. Neurosci. 24, 5537–5548[Abstract/Free Full Text]
  10. del Castillo, J., and Katz, B. (1957) Proc. R. Soc. Lond. B Biol. Sci. 146, 369–381[Medline] [Order article via Infotrieve]
  11. Monod, J., Wyman, J., and Changeux, J. P. (1965) J. Mol. Biol. 12, 88–118[Medline] [Order article via Infotrieve]
  12. Costa, T., and Herz, A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7321–7325[Abstract/Free Full Text]
  13. Leff, P. (1995) Trends Pharmacol. Sci. 16, 89–97[CrossRef][Medline] [Order article via Infotrieve]
  14. Colquhoun, D. (1998) Br. J. Pharmacol. 125, 924–947[Medline] [Order article via Infotrieve]
  15. Hu, X. Q., and Lovinger, D. M. (2005) J. Physiol. (Lond.) 568, 381–396[Abstract/Free Full Text]
  16. Hu, X. Q., Zhang, L., Stewart, R. R., and Weight, F. F. (2003) J. Biol. Chem. 278, 46583–46589[Abstract/Free Full Text]
  17. Kooyman, A. R., van Hooft, J. A., and Vijverberg, H. P. (1993) Br. J. Pharmacol. 108, 287–289[Medline] [Order article via Infotrieve]
  18. Gunthorpe, M. J., and Lummis, S. C. (1999) J. Physiol. (Lond.) 519, 713–722[Abstract/Free Full Text]
  19. Bianchi, M. T., and Macdonald, R. L. (2001) J. Neurosci. 21, 9083–9091[Abstract/Free Full Text]
  20. Jones, B. L., Whiting, P. J., and Henderson, L. P. (2006) J. Physiol. (Lond.) 573, 571–593[Abstract/Free Full Text]
  21. Beckstead, M. J., Phelan, R., Trudell, J. R., Bianchini, M. J., and Mihic, S. J. (2002) J. Neurochem. 82, 1343–1351[CrossRef][Medline] [Order article via Infotrieve]
  22. de Ligt, R. A., Kourounakis, A. P., and Ijzerman, A. P. (2000) Br. J. Pharmacol. 130, 1–12[CrossRef][Medline] [Order article via Infotrieve]
  23. Kenakin, T. (2001) FASEB J. 15, 598–611[Abstract/Free Full Text]
  24. Neelands, T. R., Fisher, J. L., Bianchi, M., and Macdonald, R. L. (1999) Mol. Pharmacol. 55, 168–178[Abstract/Free Full Text]
  25. Barrera, N. P., Herbert, P., Henderson, R. M., Martin, I. L., and Edwardson, J. M. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 12595–12600[Abstract/Free Full Text]
  26. Lummis, S. C., Beene, D. L., Lee, L. W., Lester, H. A., Broadhurst, R. W., and Dougherty, D. A. (2005) Nature 438, 248–252[CrossRef][Medline] [Order article via Infotrieve]
  27. Unwin, N. (2003) FEBS Lett. 555, 91–95[CrossRef][Medline] [Order article via Infotrieve]
  28. Kenakin, T. (1995) Trends Pharmacol. Sci. 16, 256–258[Medline] [Order article via Infotrieve]
  29. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) J. Pharmacol. Exp. Ther. 320, 1–13[Abstract/Free Full Text]
  30. Gbahou, F., Rouleau, A., Morisset, S., Parmentier, R., Crochet, S., Lin, J. S., Ligneau, X., Tardivel-Lacombe, J., Stark, H., Schunack, W., Ganellin, C. R., Schwartz, J. C., and Arrang, J. M. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 11086–11091[Abstract/Free Full Text]
  31. Grosman, C., and Auerbach, A. (2000) J. Gen. Physiol. 115, 621–635[Abstract/Free Full Text]
  32. Farrant, M., and Nusser, Z. (2005) Nat. Rev. Neurosci. 6, 215–229[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
T. Z. Deeb, D. Sharp, and T. G. Hales
Direct Subunit-Dependent Multimodal 5-Hydroxytryptamine3 Receptor Antagonism by Methadone
Mol. Pharmacol., April 1, 2009; 75(4): 908 - 917.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. R. Livesey, M. A. Cooper, T. Z. Deeb, J. E. Carland, J. Kozuska, Tim. G. Hales, J. J. Lambert, and J. A. Peters
Structural Determinants of Ca2+ Permeability and Conduction in the Human 5-Hydroxytryptamine Type 3A Receptor
J. Biol. Chem., July 11, 2008; 283(28): 19301 - 19313.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/11/6826    most recent
M707571200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, X.-Q.
Right arrow Articles by Peoples, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, X.-Q.
Right arrow Articles by Peoples, R. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement